Le Lézard
Classified in: Health
Subject: FDA

Breckenridge Announces Final Approval for Omeprazole Delayed-Release Capsules

BOCA RATON, Fla., July 5, 2017 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today it has received U.S. Food and Drug Administration final approval of its abbreviated new drug application (ANDA) for Omeprazole delayed-release capsules, USP, in 10mg, 20mg, 40mg strengths (AB rated to Prilosec®), which will be manufactured and supplied by its parent company, Laboratorios Dr. Esteve, S.A. (Barcelona, Spain).  This ANDA is part of Breckenridge's growing portfolio of vertically-integrated products with Esteve, with the product's API manufactured by Esteve's API division, Esteve Quimica.  Launch plans currently are underway.

Omeprazole Delayed-release Capsules is a proton pump inhibitor (PPI) used to treat certain stomach and esophagus issues such as GERD and ulcers.  The total combined sales for this market is $266,847,966 for the 12-month period ending April 2017, based on industry data.

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held own label Distributor that performs pharmaceutical research and development as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectables, with 39 Paragraph IV challenges filed to date. www.bpirx.com

Prilosec® is a registered trademark of AstraZeneca

SOURCE Breckenridge Pharmaceutical, Inc.

These press releases may also interest you

21 mar 2018
Prominent South Florida mold remediation and indoor environmental service company Miami Mold Specialists updates HVAC mold remediation protocols, surpasses state- and industry-recommended guidelines. Contrary to popular belief, if mold is...

21 mar 2018
Cronos Group Inc. ("Cronos Group" or the "Company") is pleased to announce that it has entered into an agreement with a syndicate of underwriters co-led by GMP Securities L.P. and BMO Capital Markets to sell 10,420,000 common shares (11,983,000...

21 mar 2018
The food recall warning issued on March 9, 2018 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. Industry is...

21 mar 2018
Cronos Group Inc. ("Cronos Group" or the "Company") is pleased to announce that it has entered into an...

21 mar 2018
An innovative program launched in 2010 in Uganda has dramatically sped the detection of outbreaks of some of the world's most dangerous viruses, according to a Centers for Disease Control and Prevention report published today in The Lancet Infectious...

21 mar 2018
Arena Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $41.50 per share. All of the shares are being sold by Arena. The gross proceeds from the...

News published on 5 july 2017 at 14:37 and distributed by: